Tarceva News and Research

RSS
Tarceva is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Tarceva is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib, erlotinib hydrochloride, and OSI-774.
AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO receives USAN, WHO generic name approval for ficlatuzumab

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Enrollment commences in belinostat-Tarceva combination trial for NSCLC

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Phase III studies should make meaningful difference in patients' quality of life: Commentary

Phase III studies should make meaningful difference in patients' quality of life: Commentary

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

New findings offer insights into novel treatment avenue for Crohn's Disease, sarcoidosis

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Targeted therapies could treat a broad range of cancers: Research

Targeted therapies could treat a broad range of cancers: Research

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

China Medical Technologies' EGFR PCR Assay for lung cancer targeted drugs receives Chinese SFDA approval

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

AVEO third quarter total collaboration revenues increase to $6.2 million

AVEO third quarter total collaboration revenues increase to $6.2 million

Sexual issues a major concern for cancer patients taking new targeted drugs

Sexual issues a major concern for cancer patients taking new targeted drugs

Allos announces favorable survival data from FOLOTYN Phase 2b study

Allos announces favorable survival data from FOLOTYN Phase 2b study

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Decision Resources: NSCLC drug market to grow from $4 billion in 2009 to over $6.5 billion in 2019

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

Global phase IV study confirms efficacy of erlotinib in treatment of non-small cell lung cancer

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

AVEO regains global rights for development, commercialization of AV-299 anti-HGF antibody candidate

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

African-American lung cancer patients with EGFR mutation respond better to erlotinib therapy

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress